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Abstract
Background: The development of resistance to cytotoxic chemotherapy continues to be a major
obstacle for successful anticancer therapy. It has been shown that cells exposed to toxic
concentrations of commonly used cancer chemotherapy agents develop DNA hypermetylation.
Hence, demethylating agents could play a role in overcoming drug resistance.
Methods: MCF-7 cells were rendered adriamycin-resistant by weekly treatment with adriamycin.
Wild-type and the resulting MCF-7/Adr cells were analyzed for global DNA methylation. DNA
methyltransferase activity and DNA methyltransferase (dnmt) gene expression were also
determined. MCF-7/Adr cells were then subjected to antisense targeting of dnmt1, -3a, and -b genes
and to treatment with the DNA methylation inhibitor hydralazine to investigate whether DNA
demethylation restores sensitivity to adriamycin.
Results:  MCF-7/Adr cells exhibited the multi-drug resistant phenotype as demonstrated by
adriamycin resistance, mdr1  gene over-expression, decreased intracellular accumulation of
adriamycin, and cross-resistance to paclitaxel. The mdr phenotype was accompanied by global
DNA hypermetylation, over-expression of dnmt genes, and increased DNA methyltransferase
activity as compared with wild-type MCF-7 cells. DNA demethylation through antisense targeting
of dnmts or hydralazine restored adriamycin sensitivity of MCF-7/Adr cells to a greater extent than
verapamil, a known inhibitor of mdr protein, suggesting that DNA demethylation interferes with
the epigenetic reprogramming that participates in the drug-resistant phenotype.
Conclusion: We provide evidence that DNA hypermethylation is at least partly responsible for
development of the multidrug-resistant phenotype in the MCF-7/Adr model and that hydralazine,
a known DNA demethylating agent, can revert the resistant phenotype.
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Background
Over the last several years, improved cancer therapies
have permitted small gains in cancer survival. Currently,
5-year relative survival rates from all sites stand at 60%
[1]. Remarkable advances in understanding neoplastic
progression at cellular and molecular levels have spurred
the discovery of molecularly targeted drugs [2]. Neverthe-
less, at present, conventional cytotoxic chemotherapy is
still used in the majority of patients with cancer who
require systemic treatment. Thus, it is vital to continue
efforts in the study of mechanisms of chemotherapy
resistance to seek means for its reversal.
While gain, loss, and mutation of genetic information
have long been known to contribute to cancer develop-
ment and progression, it is being increasingly recognized
that epigenetic defects may play an equally important
role. The pathological epigenetic changes that contribute
to cancer development include global DNA hypomethyl-
ation, hypermethylation of specific genes, chromatin
remodeling and loss of imprinting [3]. Loss of genomic
methylation is a frequent and early event in cancer, and
correlates with disease severity and metastatic potential in
many tumour types [3]. But it is generally accepted that
one of the main epigenetic modifications of the human
genome is cytosine residue methylation within the con-
text of the CpG dinucleotide as executed by at least three
functional DNA methyltransferases: dnmt1, which prefer-
entially methylates hemi-methylated DNA and plays a key
role in imprinting and X-chromosome inactivation during
embryogenesis [4], and de novo methyltransferases,
dnmt3a and dnmt3b responsible for de novo methylation
during embryogenesis and which possess equal prefer-
ence for hemi- and non-methylated DNA and that there-
fore have been classified as de novo methyltransferases
[5,6]. DNA methylation can directly interfere with the
binding of transcription factors to inhibit replication [7]
and/or methyl-CpG binding proteins that can bind to
methylated DNA, as well as regulatory proteins to inhibit
transcription [8]. In addition, both dnmt1  and methyl
binding proteins such as methyl-CpG-binding protein 2
(MeCP2) recruit histone deacetylases that by deacetyla-
tion of core histone tails lead to tighter packing of DNA
into chromatin, reducing access of transcription factors
[9,10].
De novo methylation of CpG islands in tumor suppressor
gene promoter regions may lead to transcriptional silenc-
ing through a complex process involving histone
deacetylation and chromatin condensation, and thus rep-
resents a tumorigenic event that is functionally equivalent
to genetic changes such as mutation and deletion [11].
Therefore, better understanding of epigenetic mecha-
nisms leading to tumor formation and chemoresistance
may eventually improve current cancer treatment regi-
mens and instructive for more rational use of anticancer
agents.
It has long been recognized that cultured cells exposed to
a variety of commonly used cancer chemotherapy agents,
particularly at high concentrations, develop DNA hyper-
methylation; hence, drug-induced DNA hypermethyla-
tion is thought to constitute one component of human
tumor cell response to toxic concentrations of commonly
used cancer chemotherapy agents. Thus, drug-induced
DNA hypermethylation may be capable of creating drug-
resistant phenotypes by inactivating genes whose prod-
ucts are required for drug cytotoxicity [12]. In this work
through use of an MCF-7/Adr-resistant model, we demon-
strate that DNA hypermethylation leads to drug resistance
that can be reverted by either down-regulating DNA meth-
yltranferase genes by antisense oligonucleotides or by
pharmacologic reversion of methylation by hydralazine, a
known DNA methylation inhibitor [13-16].
Methods
Cell culture
MCF-7 human breast adenocarcinoma cells were cultured
at 37°C in a humidified atmosphere containing 5% CO2
in DMEM supplemented with 10% (v/v) fetal calf serum
and sub-cultured using 0.25% trypsin with 1 mM EDTA
(Life Technologies, Inc.,). Adriamycin-resistant MCF-7
cells (MCF-7/Adr) were established in our laboratory by
intermittent exposure to adriamycin at 100 ng/mL for 1 h
every week for 20 weeks. Afterward, MCF-7/Adr cells were
routinely maintained in 200 ng/mL of adriamycin.
Cytotoxicity assays
Cells were seeded into 96-well microtiter Falcon plates
(Becton Dickinson, Franklin Lakes, NJ, USA) at 1.5–2.5 ×
103 cells/well in 0.1 mL of complete medium. The follow-
ing day, cells were treated with adriamycin, paclitaxel, cis-
platin, or 5-fluorouracil for 24 h, and subsequently cell
viability was measured by MTT dye reduction assay.
Experiments for resistance reversion were performed as
follows: Cells were cultured as previously described and
were pre-treated for 4 days with 10 μM hydralazine or for
24 h with verapamil at 5 μM. Following this, the medium
was replaced with one containing adriamycin to then
evaluate viability 24 h later. Briefly, 50 μL of 5 mg/mL
MTT reagent in PBS were added to each well. Viable cells
with active mitochondria reduce the MTT to an insoluble
purple formazan precipitate that is solubilized by the sub-
sequent addition of 150 μL of DMSO. The formazan dye
was measured spectrophotometrically using an ELISA
reader. All assays were performed in triplicate. The cyto-
toxic effect of each treatment was expressed as a percent-
age of cell viability relative to untreated control cells
(percentage of control) and is defined as [(A570 nm-treated
cells)/A570 nm-nontreated cells)] × 100.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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Nucleic acid extraction from cells
Genomic DNA was obtained with the standard method of
proteinase-K digestion and phenol-chloroform extraction.
RNA was obtained using the Trizol Reagent (Gibco BRL,
Grand Island, NY, USA) RNA extraction kit following
manufacturer instructions.
DNA methylation assays
Capillary electrophoresis. Quantification genomic 5-
methylcytosine DNA content by capillary electrophoresis
was performed as previously described [17]. Briefly, DNA
hydrolysis was carried out by incubating 40 μg of DNA in
2 mL of 88% v/v formic acid at 140°C in a sealed ampoule
for 90 min. After hydrolysis, samples were reduced to dry-
ness by speedvac concentration and redissolved in 30 μL
of Milli-Q-grade water. An uncoated fused-silica capillary
(60 cm × 75 μm; effective length, 44.5 cm) (Beckman-
Coulter was used in a CE system (P/ACE MDQ, Beckman-
Coulter) connected to a 32 Karat software data-processing
station. The running buffer was 20 mM NaCO3 (pH 9.6 ±
1) containing 80 mM SDS. Running conditions were
25°C with an operating voltage of 20 kV. On-column
absorbance was monitored at 223 nm. Prior to each run,
the capillary system was conditioned by washing with the
running buffer for 2 min. Hydrolyzed samples previously
filtered through 0.45-μm pore filters were injected under
pressure (0.5 p.s.i.) for 15 sec. Results were expressed as
absolute percentage of cytosine and 5-methylcytosine and
assays were performed in triplicate.
Cytosine-extension assay. DNA methylation was also
determined by this assay essentially as described [18]. This
assay is based on use of methylation-sensitive restriction
endonuclease that leaves a 5'guanine overhang after DNA
cleavage, with subsequent single nucleotide extension
with radiolabeled [(3)H]dCTP. Briefly, 1 μg of DNA from
cells was digested overnight with HpaII or MspI according
to manufacturer instructions. Single nucleotide extension
reaction was performed in a 25-μL reaction mixture con-
taining 0.25 μg of DNA, 1X buffer II, 1 mM MgCl, and
0.25 U of DNA polymerase [3H]dCTP (Ci/mmol) (Perkin-
Elmer, Branchburg, NJ,. USA), incubated at 56°C for 1 h,
and subsequently placed on ice. The reaction mixture was
then applied to Sephadex G25 column. For column chro-
matography, each Sephadex G25 column was centrifuged
for 10 sec at 5,000 rpm to remove the buffer, and then
loaded with the reaction mixture. After loading samples
onto the column, radiolabeled DNA was collected by col-
umn centrifugation and mixed with liquid scintillation
for determination of radioactivity. Assays were done by
triplicate and results were expressed as percentage change
from average controls
Dot blot assay. A total of 5 μg of DNA previously digested
with EcoRI for 1 h was dot-blotted onto a nitrocellulose
membrane (Bio-Rad) in a total volume of 2 μL per sam-
ple. Membranes were allowed to dry and then UV-
crosslinked for 15 sec. Membrane blocking was done by
soaking in 2.5% non-fat milk in TBS (1 h at room temper-
ature) prior to incubation with a primary sheep polyclo-
nal antibody (1:200 dilution dissolved in 2.5% TBS-T
overnight at 4°C) against 5-methylcytosine (Maine
biothecnology Services INC, Portland). Membranes were
washed three times with TBS-T, 5 min each and then incu-
bated with secondary antibody conjugated with HRP at
1:1000 dilution (Santa Cruz) for 30 min at RT, washed
with TBS-T (once for 15 minm twice for 5 min and then
once with TBS for 5 min. Membranes were incubated with
ECL reagent for 1 min and expose X-ray film in the dark
room. Signal intensity was quantified by densitometry.
Assays were done by triplicate.
DNA methyltransferase assay
The in vitro methylation assay was performed as follows:
total cell extract was obtained with lysis buffer (50 mM
Tris-HCl pH 8.0, EDTA 1 mM, 0.001% Na azide, 10 %
glycerol, 1 mM DTT, 0.06 mg/mL) (Sigma,). DNA meth-
yltransferase activity was measured employing 500 ng of a
1,112-bp fragment of the type-I Herpes simplex virus
tymidine kinase gene, which has a high GC content, in
presence of 50 mg cellular protein obtained from MCF-7
or -7/Adr cells previously exposed to 0–20 μM hydrala-
zine for 5 days. Final reaction volume (50 μL) was com-
pleted with 3 μL of S-adenosyl-L- [methyl-3H]methionine
(1 mCi/mL) (Amersham, Buckinghamshire, UK). Reac-
tions were conducted at 37°C for 2 h and stopped with
350 μL of stop solution (1% SDS, 2 mM EDTA, 0.04 g/mL
4-aminosalicylate, 125 mM NaCl, 0.25 mg/mL salmon
testis DNA, 1 mg/mL proteinase K). DNA was purified
using phenol-chloroform and precipitated with cold eth-
anol. DNA was resuspended in 30 μL of 0.3 M NaOH and
spotted on Whatman DE81 filter paper disc (Whatman,
Maidstone, UK). The disc was washed three times in 5%
trichloroacetic acid (J.T. Baker, Xalostoc, Edo. de México.
Mexico) with BSA (Research Organics, Cleveland, OH,
USA) and three times in 70% ethanol, and dried. Radioac-
tivity was measured in a Beckman liquid scintillation
counter (LS 6000TA). A blank control reaction was carried
out simultaneously using only lysis buffer. The results,
expressed in dpm, were adjusted by subtracting the back-
ground level. Each assay was performed in triplicate.
RT-PCR
Total RNA was reverse transcribed using a RT-PCR kit (Per-
kin Elmer) following manufacturer instructions. Primers
and conditions for amplifications were as follows: dnmt1,
sense AGCCTTCGGCTGACTGGCTGG antisense
CTGCCCATCATCATGACCTGG product size 150 bp,
annealing 60°C. dnmt3a, sense GACTGTATGGATGTTCT-
GTCAG antisense ATTTGTCCTGGCAGACGAAGCA prod-Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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uct size 146 bp, annealing 50°C. dnmt3b, sense
GCTGCAGACCAVCTCTGTGGCACG antisense
GCCGCCTCTTCACCATCCCG product size 81 bp,
annealing 50°C. mdr1, sense ATGTCGTTCAGATTT-
GGCCAAC antisense TCATAGATGCTGTCATTCCTGT
product size 340 bp, annealing 53°C.
Adriamycin accumulation by flow cytometry
Adriamycin is a small heterocyclic amine (molecular
mass, 580 daltons) with a pKa of 8.3 that can diffuse
across membranes in the uncharged form. Adriamycin
fluorescence is excited between 350 and 550 nm and
emits between 400 and 700 nm. MCF-7 and -MCF-7/Adr
cells were cultured in flasks and then treated for 1 h with
adriamicyn at 3 μM. Afterward, cells were harvested with
0.25% trypsin and 1 mM EDTA and centrifuged. Cell pel-
lets were washed twice with cold PBS, resuspended in 0.3
mL of PBS, and transferred to 352063 Falcon tubes. After
30 min, cell fluorescence intensity (104/mL) was deter-
mined by flow cytometry using a FAC-Scalibar (Becton
Dickinson, San Jose, CA, USA).
Antisense treatment against Dnmts
MCF-7/Adr cells were transfected with the following phos-
phorothiorate antisense oligonucleotides as previously
described [19]: DNMT1-AS, 5'-AAGCATGAGCACCGT-
TCTCC-3';  DNMT1-MM (mismatch), 5'-AACGATCAG-
GACCCTTGTCC-3';  DNMT3A-AS, 5'-
CAGGAGATGATGTCCAACCC-3';  DNMT3A-MM, 5'CA
CGACATCATCTCGAACGC-3'; DNMT3B-AS, 5'-CGTCGT-
GGCTCCAGTTACAA-3', and DNMT3B-MM,
5'CCTCGTCGGTCGACTTAGAA-3'. Over the course of 72
h, cells were transfected with 75 nM of each antisense oli-
gonucleotide every 24 h (three treatments) with 6.25 μg/
mL of lipofectine. Surviving cells were analyzed for viabil-
ity and DNA methylation 24 h after the last transfection.
Assays were done by triplicate.
Results
Generation of multi-drug resistance phenotype
As expected, MCF-7 cells receiving weekly pulses of adri-
amycin acquired the resistant phenotype. MCF-7/Adr
became resistant to adriamycin, exhibited over-expression
of the mdr1 gene, and diminished intracellular accumula-
tion of adriamycin as evaluated by flow cytometry. In
addition, MCF-7/Adr demonstrated cross-resistance to
paclitaxel but not to 5-fluorouracil and cisplatin (Figures
1a, b, c, and 1d).
Global DNA hypermethylation is associated with mdr-
phenotype
To evaluate whether or not DNA hypermethylation is
associated with drug resistance acquisition, global DNA
methylation was evaluated in MCF-7 and MCF-7/Adr. As
shown in Figure 2a, there was an increase of nearly 2% in
the absolute percentage of 5-methylcytosine (5-mC) con-
tent as evaluated by capillary electrophoresis. This obser-
vation was also corroborated by two additional methods:
cytosine-extension assay (Figure 2b), and dot blot assay
(Figure 2c).
The mdr-phenotype is associated with over-expression of 
DNA methyltransferases
The presence of global and gene promoter-specific DNA
hypermethylation in MCF-7/Adr-resistant cells suggested
changes in the methylation machinery. Thus, we analyzed
dnmt gene expression as well as DNA methyltransferase
enzymatic activity of MCF-7/Adr in comparison with
wild-type cells. Because it is known that expression of
dnmts  changes according to cycling status, cells were
growth-arrested by serum deprivation for 24 h (corrobo-
rated by flow cytometry, not shown), and then gene
expression was analyzed. Results showed clear over-
expression of dnmt1, -3a, and -b in resistant cells as com-
pared with MCF-7 cells (Figure 3a). Corresponding with
these findings, DNA methyltransferase enzymatic activity
was 40% higher in MCF-7/Adr cells (Figure 3b).
Effects of DNA methyltransferase antisense treatment on 
drug-induced hypermethylation and chemotherapy 
resistance
Despite the clear association between development of
drug resistance and DNA hypermethylation, it remains
unclear whether DNA hypermethylation contributes to
the development of drug resistance or whether it is solely
a characteristic of the resistant phenotype. With this aim,
MCF-7/Adr cells were transfected with antisense oligonu-
cleotides against each of the dnmt genes. After 72 h of anti-
sense treatment, once lack or a strong diminishing of
respective transcripts was confirmed in cells (Figure 4a),
global DNA methylation was assessed, as well as viability
with and without adriamycin treatment. Results indicate
that while treated cells with mismatch oligonucleotides
exhibited no growth inhibition with or without adriamy-
cin, the sole knocking out of dnmts in MCF-7/Adr cells led
to a small growth inhibition that, nonetheless, increased
when these cells were treated with adriamycin, as shown
in Figure 4c. Interestingly, adriamycin sensitivity was
more evident in dnmt1-, and less evident in -b, antisense-
treated cells. Sensitivity to adriamycin by means of anti-
sense treatment correlated with decreased global methyl-
ation (Figure 4b).
Drug resistance and DNA hypermethylation are reversed 
with hydralazine
Because MCF-7/Adr antisense treatment not only leads to
DNA demethylation but also to reversal of resistance, we
sought to determine whether the demethylating agent
hydralazine could also be able to restore sensitivity to
adriamycin. First, we measured the DNA methyltrans-Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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MCF-7/Adr cells show the mdr phenotype Figure 1
MCF-7/Adr cells show the mdr phenotype. a: Wild-type MCF-7 cells exposed to IC90 of adriamycin show expected 
growth inhibition, whereas MCF-7/Adr cells are resistant to adriamycin as evaluated by the MTT assay; b: RT-PCR analysis of 
the mdr1 gene demonstrates that MCF-7/Adr cells over-express the mdr1 transcript; c: Flow cytometric analysis of adriamycin-
treated cells for 1 h show that wild-type MCF-7 cells retain the majority of adriamycin inside the cell (M1); however, MCF-7/
Adr cells have essentially no drug accumulation, indicative of the presence of a functional mdr1 protein, and d: MCF-7/adr cells 
demonstrate cross-resistance to paclitaxel but not to 5-fluorouracil and cisplatin.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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ferase activity in MCF-7/Adr cells after hydralazine treat-
ment. Results demonstrate that hydralazine induces dose-
dependent decreases in DNA methyltransferase enzymatic
activity, a 30% decrease at 10 μM, the dose used for
demethylation in cell culture experiments (Figure 5a), and
that it also reduces the global DNA methylation level to
Global hypermethylation in MCF-7/Adr cells Figure 2
Global hypermethylation in MCF-7/Adr cells. a) 5-mC content was evaluated by capillary electrophoresis. Percentage of 
5-mC was 3.6% in MCF-7, while this increased to 5.6% in MCF-7/Adr cells; b) cytosine-extension assay based on use of meth-
ylation-sensitive restriction endonuclease that leaves a 5' guanine overhang after DNA cleavage with subsequent single-nucle-
otide extension with radiolabeled [(3)H]dCTP shows a 40% decrease in incorporation of radiolabeled [(3)H]dCTP by the DNA 
of HpaII-digested MCF-7/Adr cells, indicative of hypermethylation, and c), a polyclonal antibody against 5-methylcytosine was 
incubated with the digested DNA spotted in a nitrocellulose membrane. Spot intensity is 30% higher as evaluated by densito-
metric analysis in the DNA of MCF-7/Adr cells, also indicative of DNA hypermethylation.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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that observed in wild-type MCF-7 cells (Figures 5b,5c,5d).
As expected, cell viability experiments showed that
hydralazine rendered MCF-7/Adr cells sensitive to adri-
amycin at a level indistinguishable to that of wild-type
MCF-7. This restoration of sensitivity by hydralazine was
also observed when cells were treated with paclitaxel, on
which adriamycin-resistant cells showed cross-resistance
(Figure 6).
The mdr fphenotype of MCF-7/Adr cells and its reversion 
with hydralazine and verapamil
It is widely known that the MCF-7/Adr model expresses
the mdr-phenotype characterized by mdr1 gene and pro-
tein over-expression. To gain further insight into the role
that mdr plays in comparison with DNA hypermethyla-
tion for chemoresistance in this model, we decided to
determine to what extent verapamil, a known allosteric
inhibitor of the mdr protein, could reverse adriamycin
resistance in MCF-7/Adr cells. As shown in Figure 7a, adri-
amycin accumulation in MCF-7/Adr cells was almost
none. As expected, resistant verapamil-treated cells experi-
enced an increase in intracellular adriamycin accumula-
tion comparable to that with hydralazine. As there is no
data to suggest direct interaction of hydralazine with mdr
protein, we sought to determine whether hydralazine by
its demethylating effect could inhibit mdr1 gene expres-
sion. Results demonstrate that hydralazine decreases
rather than increases expression of the mdr1 (Figure 7b).
Our data demonstrates that hydralazine by its effect on
mdr1 gene expression increased cellular accumulation of
adriamycin to the same extent as verapamil; hence, we
decided to compare the individual ability of these com-
pounds to reverse resistance to adriamycin. Interestingly,
the results showed that despite that both drugs led to
comparable accumulation of adriamycin, hydralazine
rendered MCF-7/Adr more susceptible to adriamycin than
verapamil (Figure 7c).
Discussion
Earlier studies underscored that generation of a drug-
resistant phenotype was accompanied by DNA hyper-
metylation; nevertheless, no causal relationship between
these could be established [20,21]. Results of the present
work performed in a well-established model of chemore-
sistance, the MCF-7/Adr cells, demonstrate that cells
require DNA hypermetylation to acquire the mdr pheno-
type, and that once cells become resistant their sensitivity
can be restored by treatment with either a DNA methyla-
tion inhibitor or by down-regulation of dnmts with anti-
sense oligonucleotides.
Expression of DNA methyltransferase genes and DNA methyltransferase activity Figure 3
Expression of DNA methyltransferase genes and DNA methyltransferase activity. a) MCF-7 and MCF-7/Adr cells 
were growth-arrested and dnmts analyzed by RT-PCR. Wild- type cells had very low or no expression of dnmt1, -3a, and -b as 
compared with MCF-7/Adr cells; b) corresponding DNA methyltransferase activity was increased by 30% in resistant cells.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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The phenotype of MCF-7/Adr cells includes over-expres-
sion of a functional mdr, diminished intracellular accu-
mulation of adriamycin, and cross-resistance to other
agents such as paclitaxel [22]. Herein, we demonstrate
that global DNA hypermethylation is also a feature of this
model by use of capillary electrophoresis, cytosine-exten-
sion assay, and dot blot. Whether this hypermethylation
has predilection over specific regions of the genome
remains to be established. This increased methylation
results from dnmts over-expression and increased DNA
methylation enzymatic activity, as shown in Figure 3, in
which we demonstrate a clear increase in expression level
and activity in resistant cells. The exact mechanism by
which cells over-express dnmts after drug exposure
remains to be determined however, it is likely that it
results from chemotherapy-induced phosphorylation/
activation of mitogen-activated protein (MAP) kinases,
such as extracellular signal-regulated kinase (ERK) 1/2
[23] which is known to participate in the regulation of
dnmts gene expresión [24]. DNA hypermethylation has
Effects of DNA methyltransferase antisense treatment on drug-induced hypermethylation and chemotherapy resistance Figure 4
Effects of DNA methyltransferase antisense treatment on drug-induced hypermethylation and chemotherapy 
resistance. a) MCF-7/Adr cells had no expression of dnmts transcripts after 72 h of antisense treatments; b) transfected cells 
with the antisense oligonucleotides had a 5-mC content between 2 and 4%, as compared with 5.6% in untreated MCF-7Adr 
cells, and c) MTT assays demonstrate that cells transfected with mismatch (MM) oligonucleotides showed no reduced cell via-
bility and only a small reduction when challenged with adriamycin. The sole transfection with oligonucleotides against dnmts led 
to a reduction in viability between 30 and 40%, and when treated with adriamycin strong cytotoxicity was observed being 
higher for dnmt1 followed by -3a and -b.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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also been observed in drug-resistant murine neuroblast-
oma cells that exhibit over-expression of dnmt1 and -3b
[25]. These data suggest that dnmt over-expression may
aid in stress-induced epigenetic cell reprogramming as an
important prerequisite to survival [26].
The association between chemoresistance and global
hypermetylation is well established; accordingly, anti-
sense experiments demonstrated that knocking out either
one of the three dnmts reduced the 5mC content to differ-
ent extents and exhibited a discrete growth-inhibitory
effect in MCF-7/Adr cells, suggesting that changes in
methylation are crucial for these cells to maintain their
growth. Furthermore, exposure of antisense-treated cells
to adriamycin led to nearly complete restoration of sensi-
tivity to the drug. The effect upon cell viability among the
three antisense-treated cells was roughly the same; none-
theless, dnmt1 antisense-treated adriamycin cells showed
greater sensitivity restoration, suggesting that this enzyme
could play the major role in drug resistance acquisition in
this model. The precise role for the different dnmts in can-
cer development and progression remains under study;
however, it is known that there is ample variability in the
level of expression of these genes in a number of tumors.
Effects of hydralazine on DNA methylation and DNA methyltransferase activity Figure 5
Effects of hydralazine on DNA methylation and DNA methyltransferase activity. a) MCF-7/Adr cells were treated 
with increasing concentrations of hydralazine for 4 days and then DNA methyltransferase activity assayed. Hydralazine at 10 
μM decreased enzymatic activity by 30%; b) 5-mC content was also reduced by hydralazine from 5.6–2.7%; c) cytosine-exten-
sion assay also showed higher incorporation into hydralazine treated cells as reflected by the bar marked HpaII, as did (d), dot-
blot evaluation of hydralazine-treated MCF7/Adr cells.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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For instances, in a study of the expression level of all three
methyltransferase genes by RT-PCR from bladder, colon,
kidney, and pancreas tumors, mean fold increases were 4,
3.1, and 7.5 for dnmt1, -3a, and -b, respectively [27]. The
same pattern of expression degree was observed in acute
myelogenous leukemia (higher for dnmt3b, followed by -
1 and then -3a) [28] and breast carcinomas [29]; neverthe-
less, in the acute phase of chronic leukemia dnmt3a pre-
dominates over -3b  and  -1  [28], whereas in acute
lymphoblastic leukemia dnmt1  expression level was
higher than -3a and -b [30]. Thus, our finding of higher
restoration of adriamycin sensitivity in dnmt1-depleted
cells would suggest that in the MCF-7/Adr model dnmt1
exhibits the higher participation. Recently, it was shown
that in genetically modified human cancer cells including
dnmt3a- and -b-deficient cells, dnmt1 is the major de novo
methyltransferase for three different CpG island sub-
strates, suggesting that dnmt1 might be considered to pos-
sess more diverse and wide-ranging catalytic activities
than previously suspected for a simple maintenance
enzyme [31]. Nevertheless, the contribution of dnmt3a
and  -b  enzymes for the resistant phenotype cannot be
neglected. A recent study in murine neuroblastoma cells
demonstrates that over-expression of dnmt3a and -b by
transfection leads to cisplatin resistance, which can be
reverted by treating these cells with 5-azacytidine [32].
Thus, our results and those from the neuroblastoma
model clearly indicate that DNA methylation plays a cen-
tral role in onset of drug resistance.
Because of the demonstrated participation of hypermeth-
ylation for development of resistance in this model, we
wanted to determine whether the non-nucleoside inhibi-
tor of DNA methylation hydralazine [13-16] could also
restore adriamycin sensitivity. Our results demonstrate
that hydralazine decreases DNA methyltransferase activity
and methylation to levels shown in wild-type cells, this as
expected due to its methyltransferase inhibitory activity
[16] as well as due to its ability to decrease dnmt1 and -3a
gene expression [16,33].
Drug resistance and DNA hypermethylation are reversed with hydralazine Figure 6
Drug resistance and DNA hypermethylation are reversed with hydralazine. MCF-7/Adr cell viability was evaluated 
with the MTT assay after treatment with adriamycin and paclitaxel. Cells pretreated with hydralazine had their sensitivity to 
these drugs restored.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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The mdr phenotype of MCF-7/Adr cells and its reversion with hydralazine and verapamil Figure 7
The mdr phenotype of MCF-7/Adr cells and its reversion with hydralazine and verapamil. a) Untreated MCF-7/
Adr cells had no intracellular retention of adriamycin as indicated by MI, whereas verapamil and hydralazine clearly led to drug 
retention, and b) hydralazine decreased mdr1 gene expression as evaluated by RT-PCR. Figure 7c demonstrates that pre-treat-
ment with verapamil led to only a 50% decrease in viability when cells were exposed to adriamycin as compared with an 85% 
reduction achieved with hydralazine pre-treatment.Journal of Translational Medicine 2006, 4:32 http://www.translational-medicine.com/content/4/1/32
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Hydralazine is a demethylating agent that has demon-
strated the ability to down- and up-regulate a number of
genes [34] and as such, not only affects mdr1 status in our
model but also potentially other genes that could be
implicated in developing drug resistance. Thus, to evalu-
ate whether the hydralazine's reversing effect upon resist-
ance to adriamycin depends on only mdr1 or on other
transcriptional changes we compared it against verapamil,
an allosteric inhibitor of the mdr pump [35]. Interestingly,
despite that hydralazine produces a comparable effect to
that of verapamil upon adriamycin accumulation (Figure
7a), its effects were higher than those of verapamil in cyto-
toxicity assays, suggesting that its epigenetic actions reac-
tivate or down-regulate additional genes that according to
the epigenetic reprogramming hypothesis participate in
the drug-resistant phenotype. An issue not addressed in
our work was the mechanism underlying the observed
expression change at mdr1 gene. The precise mechanism
of transcriptional regulation of this gene has remained
unclear due to its complex regulatory nature, as a conse-
quence, studies performed in both cancer cell lines and
clinical samples have shown that mdr1 promoter methyl-
ation density either inversely [36-41] or directly
[42][43][44][45,46], correlates with mdr1  gene expres-
sion. Whatever the mechanism, it is now clear that
increased drug efflux potential by ABC-transporters such
as mdr1 is only one of the multiple polygenic pathways
characterizing the drug resistant state [47].
In conclusion, the results of this study in the MCF-7/Adr
model demonstrate that global DNA hypermethylation
participates in development of adriamycin resistance and
that the demethylating agent hydralazine can revert the
resistant phenotype. In this sense it has been recently
hypothetized that epigenetic reprogramming can partici-
pate in the establishment of an epigenetic mark associated
with the chemotherapy resistant phenotype and that DNA
methylation and histone deacetylation inhibitors can
restore chemotherapy sensitivity [48]. We are currenty
evaluating in phase II studies the ability of hydralazine
plus magnesium valproate, a histone deactylase inhibitor
to resensitize tumor cells to chemotherapy in refractory
solid tumors as well as their ability to improve tumor
response when these epigenetic agents are added to adri-
amycin-based neoadjuvant therapy in locally advanced
breast cancer.
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